CXCR4 and schizophrenia: Taken together, these data suggest that targeting these signaling pathways may represent a valid strategy for neurorestorative therapies for HAND and other diseases characterized by spine loss and/or CXCR4 dysregulation, such as Alzheimer’s disease (AD) and schizophrenia.